Navigating the No Surprises Act: The Hidden Costs of Ineligible Arbitration Disputes
The No Surprises Act, enacted in 2020 as part of the Consolidated Appropriations Act, was hailed as a landmark consumer protection measure . By shielding patients from unexpected out-of-network medical bills — particularly for emergency services , air ambulances , and non-emergency care at in-network facilities — it aimed to curb the predatory practices of surprise billing that plagued the U.S. healthcare system . Central to this framework is the Independent Dispute Resolution (IDR) process , a baseball-style arbitration where insurers and providers submit payment offers , and a neutral arbiter selects one as binding .
Yet , five years on , the system is buckling under its own weight . A 2024 survey by America’s Health Insurance Plans (AHIP) and the Blue Cross Blue Shield Association (BCBSA) — representing 25 health plans covering 154 million Americans — reveals a stark reality : 39% of claims submitted to IDR were ineligible for arbitration . Alarmingly , arbiters flagged only about 17% of these as improper , allowing the rest to proceed to binding determinations that often favor providers .
This discrepancy isn't just procedural ; it's a financial black hole . With providers winning the majority of disputes and securing reimbursements three to four times higher than in-network rates , ineligible claims are inflating premiums , employer costs , and ultimately , patient out-of-pocket expenses . As Mike Tuffin , AHIP’s president and CEO , noted , “The same private equity-backed outfits that created the surprise billing business model have turned to arbitration abuse as their new strategy to gouge consumers and employers .”
This article dissects the survey’s findings , analyzes their systemic implications , and offers practical strategies for stakeholders to mitigate the fallout .
The IDR Process: A Double- Edged Sword
When negotiations fail , parties have 30 business days to initiate IDR after the initial payment determination . The arbiter evaluates factors like the Qualifying Payment Amount (QPA) —a median in-network rate — the provider’s experience , market rates , and patient acuity . The “ baseball ” rule ensures no middle-ground compromise ; it’s all-or-nothing , a design that has led to contentious litigation from providers alleging bias toward insurers ’ lower QPAs .
Since the IDR portal’s April 2022 launch , filings have surged far beyond projections — hundreds of thousands per year , totaling over one million disputes through 2024–2025 . Federal data show that a small number of large , private-equity-backed groups , such as Radiology Partners and TeamHealth , dominate dispute volume , accounting for a disproportionate share of resolutions in 2023–2024.
The AHIP/BCBSA survey exposes a critical bottleneck : eligibility screening . Plans identified 33% of emergency , 45% of non-emergency , and 23% of air ambulance claims as ineligible — more than double the shares caught by arbiters (15%, 19%, and 10%, respectively ). This gap resulted in an estimated 184,500 improper disputes advancing in 2024 , contributing to $2–$2.5 billion in wasteful spending .
Unpacking the Ineligibility Epidemic
Why are so many claims slipping through ? The survey highlights recurring issues : untimely submissions , incomplete documentation , conflicts with state surprise-billing laws , and services outside the Act’s scope ( such as routine ground ambulances or elective procedures ). These are not technicalities — they’re safeguards meant to ensure IDR addresses genuine “ surprise ” scenarios .
The incentives are asymmetric . Providers , facing tight margins in fee-for-service medicine , view IDR as a high-stakes lottery with favorable odds . Multiple analyses show providers prevail in a majority of determinations , with median prevailing offers roughly 300–450% of the QPA . Insurers , by contrast , characterize the process as “ pay-to-play ” , where filing volume outweighs merit . Private equity magnifies this distortion by acquiring specialty practices , keeping them out-of-network , and flooding IDR with disputes , betting on arbiter leniency and regulatory backlog .
The fallout is multifaceted :
- Economically , it erodes the Act’s cost-containment goals . Analyses suggest that IDR- driven reimbursements exert upward pressure on commercial premiums , though the exact impact varies .
- Operationally , ineligible disputes clog the IDR portal , delaying legitimate cases and straining CMS resources — compounded by temporary staff furloughs during the 2025 federal shutdown , which paused implementation of the pending 2023 eligibility-review rule .
- Ethically , it undermines trust : patients , shielded from direct bills , still pay indirectly through rising insurance costs .
Providers counter that insurers ’ low initial offers , often pegged to opaque QPAs , force defensive filings . The American Medical Association and others argue CMS undervalues provider inputs . Yet , data show patterns of repeat offenders — a small number of groups account for most disputes , echoing pre -Act surprise-billing behaviors .
Practical Strategies for Stakeholders
For Health Plans and Insurers
- Enhance Pre -IDR Triage : Deploy AI- assisted claim audits to flag ineligible submissions early — cross-check timestamps , documentation , and state-law applicability . AHIP data indicate plans already detect twice as many ineligible disputes as arbiters ; scaling this through shared consortia could cut improper payouts by 20–30%.
- Strategic Negotiations : Prioritize batch or bundled negotiations with high-volume providers . Offer “ good-faith ” in-network contracts with upside incentives ( e.g ., 110% of QPA for quality metrics ) to dissuade arbitration abuse . Track and escalate repeat filers to regulators .
- Advocacy and Data Sharing : Collaborate on AHIP/BCBSA- style surveys to build transparency and pressure CMS for real-time eligibility APIs . Support emergency funding to finalize the stalled 2023 rule introducing automated ineligibility gates .
For Providers and Practice Groups
- Compliance Discipline : Maintain detailed submission checklists — verify the 30-day window , include complete acuity documentation , and confirm state-law applicability . For PE- backed entities , conduct monthly random audits (≈10%) to withdraw ineligible filings proactively .
- Value-Based Alternatives : Transition from volume-driven IDR reliance toward value-based or capitation models . When using IDR, emphasize patient-outcome data ( e.g ., via EHR integrations like Epic’s acuity modules ) to justify higher offers without excess .
- Balanced Litigation : Engage in advocacy for QPA transparency but pair this with self-regulatory pledges — publicly disclosing out-of-network rationales can bolster credibility .
For Policymakers and Regulators
- Streamline Oversight : Finalize the 2023 CMS rule mandating pre-screening by certified vendors and scalable filing fees for serial abusers . Consider a “ fast-track ” channel for disputes under $1,000 .
- Data-Driven Reforms : Require annual CMS reports identifying high-volume filers exceeding 5% of total disputes for audit review . Strengthen state-federal data sharing to harmonize eligibility standards .
- Consumer Safeguards : Launch HHS educational campaigns detailing patients ’ rights and how to report suspected abuse .
For Employers and Consumers
- Employers : Audit plan exposure to IDR disputes ; negotiate premium guarantees and rate-stability clauses .
- Consumers : Review Explanation of Benefits (EOB) documents for required QPA disclosures and appeal questionable charges through state regulators . Resources like Healthcare Bluebook can provide fair-price benchmarks .
Reforming for Resilience
The No Surprises Act’s IDR process , once a beacon of reform , now illustrates how well-intentioned policy can be subverted by volume and loopholes . With nearly 40% of disputes deemed ineligible and billions wasted , the system risks amplifying the very costs it sought to contain .
But the crisis is solvable . Through vigilant compliance , data transparency , and technological modernization , stakeholders can restore balance . Policymakers must act decisively — finalizing portal upgrades and refining QPA methodology could halve inefficiencies by 2027 . Until then , the AHIP/BCBSA survey should serve not as indictment , but as blueprint : for insurers , a call to fortify triage ; for providers , a nudge toward sustainable contracting ; and for policymakers , a reminder that true surprise-billing protection demands shared accountability .
Limitations & Methodological Notes
All quantitative findings are drawn from publicly available sources (AHIP/BCBSA survey 2024–2025; CMS IDR portal data ; Georgetown CHIR analyses ; KFF issue briefs ). Estimates of cost impact and eligibility rates derive from insurer-reported data and should be interpreted as indicative , not exhaustive . Independent audits and CMS validation may refine these figures in future releases .
Sources
- AHIP. New AHIP/BCBSA Survey Shows Nearly 40% of Providers ’ Surprise Billing Disputes Are Ineligible Under No Surprises Act. Oct 2025. https://www.ahip.org/news/press-releases/new-ahip-bcbsa-survey-shows-nearly-40-of-providers-surprise-billing-disputes-are-ineligible-under-no-surprises-act
- Healthcare Dive . High Volume of Surprise Billing Disputes Are Ineligible for Arbitration , Insurers Allege . Oct 2025. https://www.healthcaredive.com/news/surprise-billing-disputes-ineligible-survey-ahip-bcbsa/803785/
- Georgetown University Center on Health Insurance Reforms . The Substantial Costs of the No Surprises Act Arbitration Process. Sept 2025. https://chir.georgetown.edu/the-substantial-costs-of-the-no-surprises-act-arbitration-process/
- KFF. The No Surprises Act: Implementation and Ongoing Challenges . 2024. https://www.kff.org/health-costs/issue-brief/the-no-surprises-act-implementation-and-challenges/
- CMS. No Surprises Act Independent Dispute Resolution Portal Data Updates . Accessed Oct 2025. https://www.cms.gov/nosurprises/independent-dispute-resolution